Alumis files for IPO to support work on oral TYK2 blockers

Exclusive: In $1B+ bet on AI, biopharma heavyweights back new startup to upend drug R&D

Inscripta Acquires Infinome Biosciences, Sestina Bio

BIOS Builders Interview with Mark Chao, Co-founder & CEO at TenSixteen Bio

Foresite Labs’ new $173M fund to bankroll fewer startups but ‘big ideas’ fueled by data

Foresite Capital Launches $173M Fund to Support Incubated Companies

TenSixteen Bio Plumbs Somatic Mosaicism for Source of Multiple Diseases

TenSixteen targets dynamic genome to find driver mutations, catch cancer earlier

Foresite and GV pour $40M into startup’s move to CHIP into new disease biology

With Forty Seven co-founder at the helm, new biotech spinout launches to target mutations potentially linked to numerous diseases